Monoclonal antibodies are one of the fastest-growing classes of biopharmaceuticals and are the backbone of many treatment modalities.
Many antibodies engage the same target or target multiple members of a single signaling pathway, therefore drug developers are pushing to produce next generation antibody drugs against new targets with improved mechanisms of action, pharmacokinetics and delivery systems. The Intellicyt® iQue Screener platform provides an integrated solution that produces rapidly actionable results.
Download this application note to discover how you can:
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
© 2019 Technology Networks
All rights reserved